INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
MWN-AI** Summary
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company specializing in inflammation and immunology, is set to report its third quarter financial results for the period ending September 30, 2025, on Thursday, October 30, 2025. The company invites investors and analysts to join a conference call at 4:30 PM Eastern Time for this purpose, where it will also provide a corporate update. Participants can access the call by dialing 1-800-225-9448 or 1-203-518-9708 for international callers, using Conference ID: INMUNE. A live webcast will also be available on INmune Bio’s website, with a transcript provided approximately 24 hours post-call.
INmune Bio is focused on innovating treatments that modulate the innate immune system to combat various diseases. It operates three major product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, designed to neutralize soluble TNF—linked to immune dysfunction; CORDStrom™, a proprietary stem cell program recently completing trials for recessive dystrophic epidermolysis bullosa; and INKmune®, which aims to enhance natural killer cell responses against cancer, currently being tested in patients with metastatic castration-resistant prostate cancer.
While the company's initiatives show promise, they remain in clinical stages, meaning there is no guarantee of successful outcomes or regulatory approval. Numerous uncertainties and risks could impact the realization of projected milestones, necessitating careful consideration by investors and stakeholders. Those interested in learning more about INmune Bio and its innovative products can visit the company’s website at www.inmunebio.com. For inquiries, executives David Moss and Daniel Carlson can be contacted directly.
MWN-AI** Analysis
As INmune Bio Inc. (NASDAQ: INMB) prepares to release its third-quarter financial results on October 30, 2025, investors should closely monitor several key factors that could influence the stock's trajectory. The company, a clinical-stage biotechnology firm focusing on the innate immune system, is at a pivotal juncture. Its three product platforms—the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, CORDStrom™, and INKmune®—are in various stages of development, and their progress can significantly impact market sentiment.
Management’s forthcoming conference call on October 30 at 4:30 PM ET will be critical in unpacking the ongoing trials, updates on clinical milestones, and strategies moving forward. Investors should pay particular attention to any forward-looking statements regarding trial results, potential FDA approvals, and commercialization timelines. The company’s reliance on successful clinical outcomes and adequate funding to sustain operations underscores the inherent risks associated with biotech investments.
The completion of the blinded randomized trial for CORDStrom™ in recessive dystrophic epidermolysis bullosa and developments in the ongoing INKmune® trials for metastatic castration-resistant prostate cancer are anticipated highlights. Positive updates in these areas may catalyze the stock positively. Conversely, any setbacks or lack of progress could lead to downward revisions in market expectations.
Given the volatile nature of biotechnology stocks, it is advisable for investors to maintain a cautiously optimistic perspective. Preparing for fluctuations around the earnings announcement and conference call is prudent, with potential for both rapid growth and significant risks inherent to the sector. Investors might consider diversifying their portfolios to mitigate risks, while also keeping a watchful eye on INmune Bio’s developments to capitalise on potential upsides.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Management to host conference call and webcast at 4:30 pm ET on that day
Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that it will host a conference call on Thursday, October 30, 2025 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2025 and to provide a corporate update.
Conference Call Information
To participate in this event, dial-in approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.
Date: October 30, 2025
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-225-9448
Participant Dial-in (international): 1-203-518-9708
Conference ID: INMUNE
A live audio webcast of the call can be accessed using this link:
https://viavid.webcasts.com/starthere.jsp?ei=1733354&tp_key=a3c75da53b
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through November 13 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11159914.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. The second program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. The third program, INKmune®, is designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer. To learn more, please visit www.inmunebio.com .
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of diseases, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contacts:
David Moss
Chief Executive Officer
(858) 964-3720
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
What are the key learnings from the recent clinical trials for INmune Bio Inc. INMB, particularly regarding the efficacy and safety of your current product platforms?
How does INmune Bio Inc. INMB plan to address potential funding challenges to sustain its research and development initiatives in the upcoming quarters?
Can you provide updates on any partnerships or collaborations that INmune Bio Inc. INMB is pursuing to enhance product development and market reach?
What are the most significant milestones INmune Bio Inc. INMB anticipates achieving in the next 6-12 months that could impact investor perceptions and the company’s strategic direction?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
-3.93% G/L:
$1.59 Last:
342,332 Volume:
$1.66 Open:
